Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 20/20 | 0.82 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.82 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.82 |
| ▸ | FLT3 | P36888 | 5/20 | 0.82 |
| ▸ | KIT | P10721 | 2/20 | 0.82 |
| ▸ | LCK | P06239 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.82 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vimseltinib SCHEMBL16047448 | 0.90 | CSF1R (1.00) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| Vimseltinib SCHEMBL30453793 | 0.90 | CSF1R (1.00) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL31740962 | 0.90 | CSF1R (0.70) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| Vimseltinib SCHEMBL31615255 | 0.90 | CSF1R (0.98) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL31740343 | 0.82 | CSF1R (0.57) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL16046817 | 0.79 | CSF1R (0.80) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL25909908 | 0.78 | CSF1R (0.79) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL16046264 | 0.78 | CSF1R (1.00) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL29222872 | 0.77 | CSF1R (0.54) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL30825676 | 0.77 | CSF1R (0.54) | CSF1RPDGFRAPDGFRBFLT3KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617775-B2 | Processes of making CSF-1R inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250368622-A1 | PROCESSES OF MAKING CSF-1R INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2025-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617775-B2 | Processes of making CSF-1R inhibitors and methods of use thereof | CSF1R, CSF3R, FLT3 | CSF1R 1/4885PDGFRA 41/4885PDGFRB 27/4885 |
| US-20250368622-A1 | PROCESSES OF MAKING CSF-1R INHIBITORS AND METHODS OF USE THEREOF | CSF3R, CSF1R, FLT3 | CSF1R 2/4885PDGFRA 149/4885PDGFRB 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.